"There are limited long-term studies of these drugs on patients with obesity, particularly those who do not have diabetes or other related chronic conditions." Prior auth, AI, provider directories A host of new actions addressing prior auth is proposed in the rule
for many people the effects are mild and manageable, while for a minority they become limiting
Support WBURWhat's behind the push to make peptide therapies more readily availableWill StoneJuly 08, 2026 ShareFederal regulators are considering allowing compounding pharmacies to manufacture several peptides that are currently popular among consumers
Sarcopenia in elderly diabetic patients: Role of dipeptidyl peptidase 4 inhibitors
Apart from apparently affecting the synthesis of growth hormone, scientists also suggest that CJC-1295 may interact with the survival and proliferation of the cells that synthesize it - the somatotroph cells in the anterior pituitary gland
An announcement by one pharmacy benefit manager that it was narrowing its formulary to a single GLP-1 for obesity could help drive lower costs
